HepaRegeniX GmbH achieves successful proof of efficacy in acute liver disease models for selected MKK4 inhibitors
Preclinical data indicate unique liver disease treatment potential as demonstrated by strong liver regeneration and significant reduction in steatosis plus inhibition of apoptosis
Tubingen (Germany), July 07, 2020 – HepaRegeniX GmbH, a preclinical stage company developing novel therapies for the treatment of acute and chronic liver diseases, announced today successful proof of efficacy for MKK4 inhibitors in several acute liver disease models. Underlying preclinical data showed strong inhibition of apoptosis in a standard CCl4-induced murine liver failure model upon treatment with several small molecule inhibitors targeting MKK4 (Mitogen-Activated Protein (MAP) Kinase 4). Likewise, pronounced anti-steatotic effects were observed for those compounds in a proprietary alcohol-induced steatosis model in collaboration with the University Hospital of Tübingen (Germany).